Philippines Suspends Dengue Shots after Drug Firm’s Warning

December 1, 2017

(New York Times) – The Philippines suspended its school-based dengue immunization program on Friday after the French pharmaceutical giant Sanofi warned that its flagship vaccine, Dengvaxia, had been found to pose health risks in people not previously infected. The suspension came after health experts expressed worries about Sanofi’s announcement this week. The company said further clinical studies had revealed that, in those who had previously had dengue, the vaccine could prevent repeat infection. But for those who had not had dengue, and were vaccinated and later became infected, “more cases of severe disease could occur,” Sanofi said in the advisory.

Recommended Reading